Germany Genomics Market

ID: MRFR/LS/50703-HCR
200 Pages
Vikita Thakur
Last Updated: February 06, 2026
Germany Genomics Market Research Report: Size, Share, Trend Analysis By Applications (Drug Discovery, Clinical Diagnostics, Personalized Medicine, Genetic Testing), By Technology (Sequencing, Microarray, PCR, CRISPR), andBy End Use (Hospitals, Diagnostic Laboratories, Research Institutes, Pharmaceutical Companies) - Growth Outlook & Industry Forecast 2025 To 2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.

Germany Genomics Market

Market Size

Forecast Period2025 - 2035
CAGR (2025 - 2035)12.59%
2024 Market Size$ 3,644.81 Million
2025 Market Size$ 4,103.69 Million
2035 Market Size$ 13,431 Million

Key Players

Illumina
Thermo Fisher Scientific
Roche
Agilent Technologies
BGI Genomics
Qiagen
Trends
  • Personalized Medicine Adoption
  • Technological Advancements
  • Regulatory Support and Funding
Opportunities
  • Investment in Genomic Research
  • Regulatory Framework Enhancements
  • Rising Demand for Genetic Testing
Summary Table of Contents Segmentation Download PDF
  1. 1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
    1. 1.1 EXECUTIVE SUMMARY
      1. 1.1.1 Market Overview
      2. 1.1.2 Key Findings
      3. 1.1.3 Market Segmentation
      4. 1.1.4 Competitive Landscape
      5. 1.1.5 Challenges and Opportunities
      6. 1.1.6 Future Outlook
  2. 2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
    1. 2.1 MARKET INTRODUCTION
      1. 2.1.1 Definition
      2. 2.1.2 Scope of the study
        1. 2.1.2.1 Research Objective
        2. 2.1.2.2 Assumption
        3. 2.1.2.3 Limitations
    2. 2.2 RESEARCH METHODOLOGY
      1. 2.2.1 Overview
      2. 2.2.2 Data Mining
      3. 2.2.3 Secondary Research
      4. 2.2.4 Primary Research
        1. 2.2.4.1 Primary Interviews and Information Gathering Process
        2. 2.2.4.2 Breakdown of Primary Respondents
      5. 2.2.5 Forecasting Model
      6. 2.2.6 Market Size Estimation
        1. 2.2.6.1 Bottom-Up Approach
        2. 2.2.6.2 Top-Down Approach
      7. 2.2.7 Data Triangulation
      8. 2.2.8 Validation
  3. 3 SECTION III: QUALITATIVE ANALYSIS
    1. 3.1 MARKET DYNAMICS
      1. 3.1.1 Overview
      2. 3.1.2 Drivers
      3. 3.1.3 Restraints
      4. 3.1.4 Opportunities
    2. 3.2 MARKET FACTOR ANALYSIS
      1. 3.2.1 Value chain Analysis
      2. 3.2.2 Porter's Five Forces Analysis
        1. 3.2.2.1 Bargaining Power of Suppliers
        2. 3.2.2.2 Bargaining Power of Buyers
        3. 3.2.2.3 Threat of New Entrants
        4. 3.2.2.4 Threat of Substitutes
        5. 3.2.2.5 Intensity of Rivalry
      3. 3.2.3 COVID-19 Impact Analysis
        1. 3.2.3.1 Market Impact Analysis
        2. 3.2.3.2 Regional Impact
        3. 3.2.3.3 Opportunity and Threat Analysis
  4. 4 SECTION IV: QUANTITATIVE ANALYSIS
    1. 4.1 Pharmaceutical, BY Application (USD Million)
      1. 4.1.1 Drug Discovery
      2. 4.1.2 Clinical Diagnostics
      3. 4.1.3 Personalized Medicine
      4. 4.1.4 Genetic Testing
    2. 4.2 Pharmaceutical, BY Technology (USD Million)
      1. 4.2.1 Sequencing
      2. 4.2.2 Microarray
      3. 4.2.3 PCR
      4. 4.2.4 CRISPR
    3. 4.3 Pharmaceutical, BY End Use (USD Million)
      1. 4.3.1 Hospitals
      2. 4.3.2 Diagnostic Laboratories
      3. 4.3.3 Research Institutes
      4. 4.3.4 Pharmaceutical Companies
  5. 5 SECTION V: COMPETITIVE ANALYSIS
    1. 5.1 Competitive Landscape
      1. 5.1.1 Overview
      2. 5.1.2 Competitive Analysis
      3. 5.1.3 Market share Analysis
      4. 5.1.4 Major Growth Strategy in the Pharmaceutical
      5. 5.1.5 Competitive Benchmarking
      6. 5.1.6 Leading Players in Terms of Number of Developments in the Pharmaceutical
      7. 5.1.7 Key developments and growth strategies
        1. 5.1.7.1 New Product Launch/Service Deployment
        2. 5.1.7.2 Merger & Acquisitions
        3. 5.1.7.3 Joint Ventures
      8. 5.1.8 Major Players Financial Matrix
        1. 5.1.8.1 Sales and Operating Income
        2. 5.1.8.2 Major Players R&D Expenditure. 2023
    2. 5.2 Company Profiles
      1. 5.2.1 Illumina (US)
        1. 5.2.1.1 Financial Overview
        2. 5.2.1.2 Products Offered
        3. 5.2.1.3 Key Developments
        4. 5.2.1.4 SWOT Analysis
        5. 5.2.1.5 Key Strategies
      2. 5.2.2 Thermo Fisher Scientific (US)
        1. 5.2.2.1 Financial Overview
        2. 5.2.2.2 Products Offered
        3. 5.2.2.3 Key Developments
        4. 5.2.2.4 SWOT Analysis
        5. 5.2.2.5 Key Strategies
      3. 5.2.3 Roche (CH)
        1. 5.2.3.1 Financial Overview
        2. 5.2.3.2 Products Offered
        3. 5.2.3.3 Key Developments
        4. 5.2.3.4 SWOT Analysis
        5. 5.2.3.5 Key Strategies
      4. 5.2.4 Agilent Technologies (US)
        1. 5.2.4.1 Financial Overview
        2. 5.2.4.2 Products Offered
        3. 5.2.4.3 Key Developments
        4. 5.2.4.4 SWOT Analysis
        5. 5.2.4.5 Key Strategies
      5. 5.2.5 BGI Genomics (CN)
        1. 5.2.5.1 Financial Overview
        2. 5.2.5.2 Products Offered
        3. 5.2.5.3 Key Developments
        4. 5.2.5.4 SWOT Analysis
        5. 5.2.5.5 Key Strategies
      6. 5.2.6 Qiagen (DE)
        1. 5.2.6.1 Financial Overview
        2. 5.2.6.2 Products Offered
        3. 5.2.6.3 Key Developments
        4. 5.2.6.4 SWOT Analysis
        5. 5.2.6.5 Key Strategies
      7. 5.2.7 PerkinElmer (US)
        1. 5.2.7.1 Financial Overview
        2. 5.2.7.2 Products Offered
        3. 5.2.7.3 Key Developments
        4. 5.2.7.4 SWOT Analysis
        5. 5.2.7.5 Key Strategies
      8. 5.2.8 Eurofins Scientific (LU)
        1. 5.2.8.1 Financial Overview
        2. 5.2.8.2 Products Offered
        3. 5.2.8.3 Key Developments
        4. 5.2.8.4 SWOT Analysis
        5. 5.2.8.5 Key Strategies
      9. 5.2.9 Genomatix (DE)
        1. 5.2.9.1 Financial Overview
        2. 5.2.9.2 Products Offered
        3. 5.2.9.3 Key Developments
        4. 5.2.9.4 SWOT Analysis
        5. 5.2.9.5 Key Strategies
    3. 5.3 Appendix
      1. 5.3.1 References
      2. 5.3.2 Related Reports
  6. 6 LIST OF FIGURES
    1. 6.1 MARKET SYNOPSIS
    2. 6.2 GERMANY MARKET ANALYSIS BY APPLICATION
    3. 6.3 GERMANY MARKET ANALYSIS BY TECHNOLOGY
    4. 6.4 GERMANY MARKET ANALYSIS BY END USE
    5. 6.5 KEY BUYING CRITERIA OF PHARMACEUTICAL
    6. 6.6 RESEARCH PROCESS OF MRFR
    7. 6.7 DRO ANALYSIS OF PHARMACEUTICAL
    8. 6.8 DRIVERS IMPACT ANALYSIS: PHARMACEUTICAL
    9. 6.9 RESTRAINTS IMPACT ANALYSIS: PHARMACEUTICAL
    10. 6.10 SUPPLY / VALUE CHAIN: PHARMACEUTICAL
    11. 6.11 PHARMACEUTICAL, BY APPLICATION, 2024 (% SHARE)
    12. 6.12 PHARMACEUTICAL, BY APPLICATION, 2024 TO 2035 (USD Million)
    13. 6.13 PHARMACEUTICAL, BY TECHNOLOGY, 2024 (% SHARE)
    14. 6.14 PHARMACEUTICAL, BY TECHNOLOGY, 2024 TO 2035 (USD Million)
    15. 6.15 PHARMACEUTICAL, BY END USE, 2024 (% SHARE)
    16. 6.16 PHARMACEUTICAL, BY END USE, 2024 TO 2035 (USD Million)
    17. 6.17 BENCHMARKING OF MAJOR COMPETITORS
  7. 7 LIST OF TABLES
    1. 7.1 LIST OF ASSUMPTIONS
  8. 7.1.1
    1. 7.2 Germany MARKET SIZE ESTIMATES; FORECAST
      1. 7.2.1 BY APPLICATION, 2025-2035 (USD Million)
      2. 7.2.2 BY TECHNOLOGY, 2025-2035 (USD Million)
      3. 7.2.3 BY END USE, 2025-2035 (USD Million)
    2. 7.3 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
  9. 7.3.1
    1. 7.4 ACQUISITION/PARTNERSHIP
  10. 7.4.1

Germany Pharmaceutical Market Segmentation

Pharmaceutical By Application (USD Million, 2025-2035)

  • Drug Discovery
  • Clinical Diagnostics
  • Personalized Medicine
  • Genetic Testing

Pharmaceutical By Technology (USD Million, 2025-2035)

  • Sequencing
  • Microarray
  • PCR
  • CRISPR

Pharmaceutical By End Use (USD Million, 2025-2035)

  • Hospitals
  • Diagnostic Laboratories
  • Research Institutes
  • Pharmaceutical Companies

Related Reports

No regional reports available for this market.

No country-specific reports available for this market.

Customer Stories

Case Study Cover Image
Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035